CELC Stock Overview
A clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Celcuity Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$13.19 |
| 52 Week High | US$22.19 |
| 52 Week Low | US$11.51 |
| Beta | 0.75 |
| 11 Month Change | -15.50% |
| 3 Month Change | -24.41% |
| 1 Year Change | -4.00% |
| 33 Year Change | -13.56% |
| 5 Year Change | 23.27% |
| Change since IPO | -7.70% |
Recent News & Updates
Celcuity: Breast Cancer Drug Developer With Upcoming Catalysts
Nov 06Is Celcuity (NASDAQ:CELC) Using Too Much Debt?
Aug 31
Celcuity: Flying A Phase 3 Trial Right Under Your Nose
Jul 05Recent updates
Celcuity: Breast Cancer Drug Developer With Upcoming Catalysts
Nov 06Is Celcuity (NASDAQ:CELC) Using Too Much Debt?
Aug 31Celcuity: Flying A Phase 3 Trial Right Under Your Nose
Jul 05Does Celcuity (NASDAQ:CELC) Have A Healthy Balance Sheet?
May 08Is Celcuity (NASDAQ:CELC) Using Too Much Debt?
Jul 04Is Celcuity (NASDAQ:CELC) A Risky Investment?
Sep 13Celcuity rises after hours on FDA Breakthrough Therapy nod for its breast cancer treatment
Jul 18Is Celcuity (NASDAQ:CELC) A Risky Investment?
Jan 27Health Check: How Prudently Does Celcuity (NASDAQ:CELC) Use Debt?
Sep 21Celcuity: Nipping The Oncogenic Bud
Jul 08What You Need To Know About Celcuity Inc.'s (NASDAQ:CELC) Investor Composition
Mar 14We're Hopeful That Celcuity (NASDAQ:CELC) Will Use Its Cash Wisely
Jan 20Celcuity inks clinical trial pact with Massachusetts General Hospital and Puma Technologies
Dec 23Could The Celcuity Inc. (NASDAQ:CELC) Ownership Structure Tell Us Something Useful?
Nov 29Celcuity EPS beats by $0.03
Nov 09Shareholder Returns
| CELC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 4.2% | 2.5% | 2.2% |
| 1Y | -4.0% | 16.1% | 31.6% |
Return vs Industry: CELC underperformed the US Biotechs industry which returned 16.2% over the past year.
Return vs Market: CELC underperformed the US Market which returned 31.7% over the past year.
Price Volatility
| CELC volatility | |
|---|---|
| CELC Average Weekly Movement | 6.5% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CELC has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CELC's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 55 | Brian Sullivan | www.celcuity.com |
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company’s CELsignia diagnostic platform uses a patient’s living tumor cells to identify the specific abnormal cellular process driving a patient’s cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer.
Celcuity Inc. Fundamentals Summary
| CELC fundamental statistics | |
|---|---|
| Market cap | US$489.74m |
| Earnings (TTM) | -US$93.97m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.2x
P/E RatioIs CELC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CELC income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$93.97m |
| Earnings | -US$93.97m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.53 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 64.7% |
How did CELC perform over the long term?
See historical performance and comparison